Characteristics of Macular Microvascular Changes in Patients with Systemic Lupus Erythematosus
Lulu Bao1 , Hong Wang2 , Yufei Wu1 , Rong Zhou1 , Meixiao Shen1 , Qi Chen1
1 Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China 2 The Second Affiliated Hospital &Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China
Objective: To observe the characteristics of early macular microvascular changes in patients with systemic lupus erythematosus using optical coherence tomography angiography (OCTA). Methods: This was a retrospective series of case study. Thirty-one patients (62 eyes) who were diagnosed with SLE by the Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University from May to November 2018, were divided into a lupus retinopathy (LR) group of 10 patients (17 eyes) and a non-lupus retinopathy group of 24 patients (45 eyes). At the same time, 35 healthy subjects (35 eyes) who were matched by age and sex with the disease groups were recruited as a control group. All subjects had a 3 mm×3 mm area of the macula scanned by OCTA to obtain superficial and deep retinal microvascular images of the macular area, and retinal blood flow density maps were skeletonized and analyzed by a custom automated algorithm. The total annular zone (TAZ), with a diameter of 2.5 mm, was obtained after excluding the foveal avascular zone (FAZ, 0.6 mm), and the superficial and deep retinal skeletonized capillary densities (RCD) of the TAZ were further divided into 4 regions (S, T, I, N). In addition, disease activity of the patients was assessed using the SLE disease activity index (SLEDAI). Data analysis was performed using a t test and analysis of variance. Results: The RCD of the superficial retinal capillary plexus (SRCP) were found to be significantly lower in the NLR and LR groups than in the control group, and the LR group was even lower than the NLR group and the difference was significant (P<0.05). In the deep retinal capillary plexus (DRCP), the difference between the three groups was not as obvious as that in the superficial layer. Only the RCD of the LR group in the N region was significantly lower than that in the NLR group (P=0.022), which were also lower than those in the control group (P<0.05) except for the T region. In addition, the score of SLEDAI in the LR group was significantly higher than in the NLR group (P=0.006), and the incidence of SLE complications such as lupus nephritis and neuropsychiatric SLE were higher in the LR group (50% vs. 25%, 10% vs. 4% respectively). Conclusions: OCTA can effectively detect early changes in macular microvascular morphology in the patients with SLE. In patients with SLE without significant fundus and visual impairment, the RCD of SRCP is significantly altered, suggesting that it may be used as an early biomarker for monitoring SLE retinal damage.
Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol, 2016, 100(1): 135-141. DOI: 10.1136/bjophthalmol-2015-306629.
[3]
Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: A review of the literature. Autoimmune Dis, 2012, 2012: 290898. DOI: 10.1155/2012/ 290898.
[4]
Sivaraj RR, Durrani OM, Denniston AK, et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford), 2007, 46(12): 1757-1762. DOI: 10.1093/rheumatology/ kem173.
[5]
Ushiyama O, Ushiyama K, Koarada S, et al. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis, 2000, 59(9): 705-708. DOI: 10.1136/ard.59.9.705.
[6]
Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med, 2018, 18(2): 135-149. DOI: 10.1007/s10238-017-0479-9.
[7]
Kharel Sitaula R, Shah DN, Singh D. Role of lupus retinopathy in systemic lupus erythematosus. J Ophthalmic Inflamm Infect, 2016, 6(1): 15. DOI: 10.1186/s12348-016-0081-4.
Seth G, Chengappa KG, Misra DP, et al. Lupus retinopathy: A marker of active systemic lupus erythematosus. Rheumatol Int, 2018, 38(8): 1495-1501. DOI: 10.1007/s00296-018-4083-4.
[10]
Gao N, Li MT, Li YH, et al. Retinal vasculopathy in patients with systemic lupus erythematosus. Lupus, 2017, 26(11): 1182- 1189. DOI: 10.1177/0961203317698050.
[11]
Tolba DA, El-Fayoumi D, Abdelaziz MS, et al. Fluorescein angiographic findings in patients with active systemic lupus erythematosus. Ocul Immunol Inflamm, 2017, 25(6): 884-890. DOI: 10.1080/09273948.2016.1192653.
[12]
Nesper PL, Roberts PK, Onishi AC, et al. Quantifying microvascular abnormalities with increasing severity of diabetic retinopathy using optical coherence tomography angiography. Invest Ophthalmol Vis Sci, 2017, 58(6): BIO307-BIO315. DOI: 10.1167/iovs.17-21787.
[13]
Chen Q, Tan F, Wu Y, et al. Characteristics of retinal structural and microvascular alterations in early type 2 diabetic patients. Invest Ophthalmol Vis Sci, 2018, 59(5): 2110-2118. DOI: 10.1167/iovs.17-23193.
[14]
Chen Q, Ma Q, Wu C, et al. Macular vascular fractal dimension in the deep capillary layer as an early indicator of microvascular loss for retinopathy in type 2 diabetic patients. Invest Ophthalmol Vis Sci, 2017, 58(9): 3785-3794. DOI: 10.1167/ iovs.17-21461.
[15]
Richter GM, Sylvester B, Chu Z, et al. Peripapillary microvasculature in the retinal nerve fiber layer in glaucoma by optical coherence tomography angiography: Focal structural and functional correlations and diagnostic performance. Clin Ophthalmol, 2018, 12: 2285-2296. DOI: 10.2147/OPTH. S179816.
[16]
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25(11): 1271-1277. DOI: 10.1002/art.1780251101.
[17]
Shen C, Yan S, Du M, et al. Assessment of capillary dropout in the superficial retinal capillary plexus by optical coherence tomography angiography in the early stage of diabetic retinopathy. BMC Ophthalmol, 2018,18(1): 113. DOI: 10.1186/ s12886-018-0778-2.
[18]
Kwapong WR, Peng C, He Z, et al. Altered macular microvasculature in neuromyelitis optica spectrum disorders. Am J Ophthalmol, 2018, 192: 47-55. DOI: 10.1016/j.ajo.2018. 04.026.
[19]
Gao SS, Jia Y, Liu L, et al. Compensation for reflectance variation in vessel density quantification by optical coherence tomography angiography. Invest Ophthalmol Vis Sci, 2016, 57(10): 4485-4492. DOI: 10.1167/iovs.16-20080.
[20]
Jia Y, Tan O, Tokayer J, et al. Split-spectrum amplitudedecorrelation angiography with optical coherence tomography. Opt Express, 2012, 20(4): 4710-4725. DOI: 10.1364/OE.20. 004710.
[21]
Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol, 2016, 30(2): 117-121. DOI: 10.1016/j.sjopt.2016.02.001.
[22]
Kinouchi R, Kinouchi M, Ishibazawa A, et al. Macular capillary recovery in systemic lupus erythematosus complicated by Kikuchi-Fujimoto disease. Int Ophthalmol, 2018, 38(4): 1797- 1801. DOI: 10.1007/s10792-017-0650-z.
[23]
Mizuno Y, Nishide M, Wakabayashi T, et al. OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE. Ann Rheum Dis, 2018. DOI: 10.1136/annrheumdis-2018-214751.
[24]
Nakamura A, Yokoyama T, Kodera S, et al. Ocular fundus lesions in systemic lupus erythematosus model mice. Jpn J Ophthalmol, 1998, 42(5): 345-351.
[25]
Bonnin S, Mané V, Couturier A, et al. New insight into the macular deep vascular plexus imaged by optical coherence tomography angiography. Retina, 2015, 35(11): 2347-2352. DOI: 10.1097/IAE.0000000000000839.
[26]
Md Noh UK, Zahidin AZ, Yong TK. Retinal vasculitis in systemic lupus erythematosus: An indication of active disease. Clin Pract, 2012, 2(2): e54. DOI: 10.4081/cp.2012.e54.
[27]
Ahn SJ, Ryu SJ, Joung JY, et al. Choroidal thinning associated with hydroxychloroquine retinopathy. Am J Ophthalmol, 2017, 183: 56-64. DOI: 10.1016/j.ajo.2017.08.022.
[28]
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol, 2014, 132(12): 1453-1460. DOI: 10.1001/jamaophthalmol. 2014.3459.
[29]
Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology, 2016, 123(6): 1386-1394. DOI: 10.1016/j.ophtha.2016.01.058.